Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be ...
Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...